newsfilter
← Latest News
GlobeNewswire·

MacroGenics Reports First Quarter 2026 Financial Results and Highlights Business Transformation

Manufacturing operations divestiture sharpens focus on core capabilities in novel drug discovery and developmentManufacturing divestiture and expanded monetization of ZYNYZ royalty anticipated to provide up to $202.5